KAON CL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KAON CL (KAON CL).
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
| Metabolism | Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination. |
| Excretion | Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%). |
| Half-life | Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease). |
| Protein binding | Minimal protein binding (<1%); not significantly bound to plasma proteins. |
| Volume of Distribution | Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration. |
| Bioavailability | Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high. |
| Onset of Action | Oral solution: onset within 30 minutes; extended-release tablets: slower onset, typically 1–2 hours. |
| Duration of Action | Effect lasts 2–4 hours for immediate-release formulations; extended-release products maintain effect for 8–12 hours with careful dosing to avoid hyperkalemia. |
Oral: 20 mEq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 mEq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 10-50 mL/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 mL/min: contraindicated due to risk of hyperkalemia. |
| Liver impairment | No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances. |
| Pediatric use | Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 mEq/kg/day in divided doses, not to exceed 1 mEq/kg per single dose or maximum 4 mEq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed. |
| Geriatric use | Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 mEq twice daily) with close monitoring of serum potassium and renal function. Avoid if eGFR < 30 mL/min/1.73 m². |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KAON CL (KAON CL).
| Breastfeeding | Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding. |
| Teratogenic Risk | Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester. |
| Fetal Monitoring | Monitor serum potassium levels periodically during pregnancy; fetal monitoring only if maternal electrolyte imbalance occurs. |
■ FDA Black Box Warning
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
| Serious Effects |
["Hyperkalemia","Severe renal impairment (oliguria, anuria, or azotemia)","Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution)","Untreated Addison's disease","Acute dehydration or heat cramps"]
| Precautions | ["Hyperkalemia risk, especially in renal impairment","Avoid solid oral forms in patients with esophageal stricture or delayed GI transit","May exacerbate metabolic alkalosis","Monitor serum potassium levels regularly"] |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility. |